Reshaping the future of patient care.
The ECOG-ACRIN Cancer Research Group designs and conducts clinical trials across
the entire cancer care continuum. With our integrated focus on therapeutic, diagnostic,
preventative, and biomarker-driven trials, we are poised to achieve patient-centered
research breakthroughs.
ECOG-ACRIN was announced in March 2011, as the result of the merger between two
highly respected Cancer Cooperative Groups: the Eastern Cooperative Oncology Group
(ECOG) and the American College of Radiology Imaging Network (ACRIN). These two
organizations bring together complementary capabilities and experience:
- ECOG’s large-scale cancer treatment clinical trials for major diseases have
changed the standard of care for cancer patients and helped to individualize their
therapy.
- ACRIN’s clinical trials encompass the full range of medical imaging research,
from landmark cancer screening trials to early phase trials evaluating imaging
biomarkers and novel imaging technologies.
Together, ECOG-ACRIN offers a bold, integrated scientific program with unique
capabilities to detect, treat, and ultimately prevent cancer. Our members gain the
distinct advantage of working with an experienced and innovative organization that is
driving the industry in the use of data-driven research.
Our merger is pervasive: we have integrated all of our research programs and staff
into a single collaborative organization. To that end, laboratory programs focused on
genetics, targeted therapy, and biomarkers will be integrated with the best and newest
technologies in functional imaging to describe the biology of tumors.
Additionally, researchers working within the integrated ECOG-ACRIN scientific
platform will be able to investigate problems that relate to specific diseases, as
well as those across diseases, and studies will be driven more by process than the
classic definition of disease.